Crispr/cas12f enzyme and system

A vector system, comprising:

• (a) a first regulatory element operably linked to a polynucleotide sequence encoding a guide RNA, the guide RNA comprising a targeting sequence linked to a direct repeat sequence, wherein the targeting sequence is capable of hybridizing to a target sequence;
• and
• (b) a second regulatory element operably linked to a nucleotide sequence encoding a CRISPR-Cas effector protein, wherein the CRISPR-Cas effector protein comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 20, or SEQ ID NO:
• 21, or having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions compared to SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 20, or SEQ ID NO:
• 21, and the CRISPR-Cas effector protein is capable of forming a CRISPR complex with the guide RNA in the absence of tracrRNA;
• wherein the first regulatory element and the second regulatory element are located on a same vector or on different vectors of the vector system;
• wherein, when transcribed, the targeting sequence hybridizes to the target sequence, the target sequence is located at a 3′ end of a protospacer adjacent motif (PAM), and the guide RNA forms a complex with the CRISPR-Cas effector protein.

A method of preparing a formulation, comprising using a CRISPR-Cas effector protein, wherein the formulation is configured for:

• (i) isolated gene or genome editing;
• (ii) a detection of an isolated single-stranded DNA;
• (iii) editing the target sequence in a target locus to modify an organism or non-human organism;
• (iv) treating a disease caused by defects in the target sequence in the target locus;
• wherein the CRISPR-Cas effector protein comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2, or having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2.

A method of nucleic acid editing, comprising contacting a CRISPR-Cas effector protein or a delivery composition with the target gene, or delivering the CRISPR-Cas effector protein or the delivery composition to a cell containing the target gene;

• furthermore,
• wherein the nucleic acid editing comprises gene or genome editing, and the gene or genome editing comprises modifying a gene, knocking out a gene, gene base substitution, a altering an expression of a gene product or regulating a gene expression, repairing a mutation, and/or inserting a polynucleotide;
• wherein the CRISPR-Cas effector protein comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2, or having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2.

A method of producing a plant having a modified trait of interest encoded by a gene of interest, comprising contacting a plant cell with a CRISPR-Cas effector protein or a delivery composition, thereby modifying or introducing the gene of interest, and regenerating the plant from the plant cell, wherein the delivery composition comprises a delivery vehicle and the CRISPR-Cas effector protein, wherein the CRISPR-Cas effector protein comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO:

• 1 or SEQ ID NO:
• 2, or having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2.

A method of identifying a trait of interest in a plant, the trait of interest being encoded by a gene of interest, the method comprising contacting a plant cell with a CRISPR-Cas effector protein or a delivery composition, thereby identifying the gene of interest;

• wherein the delivery composition comprises a delivery vehicle and the CRISPR-Cas effector protein, wherein the CRISPR-Cas effector protein comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2, or having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, or additions compared to SEQ ID NO:
• 1 or SEQ ID NO:
• 2.